People diagnosed with multiple sclerosis frequently experience continuous functional decline even when undergoing treatment with disease-modifying therapies that successfully suppress clinical relapses. This phenomenon, widely documented in scientific literature as progression independent of relapse activity, highlights the reality that multiple sclerosis acts as a biological continuum where neurodegenerative processes operate from the earliest stages of the disease rather than emerging solely during later phases. Traditional clinical monitoring relies heavily on the Expanded Disability Status Scale, but this metric is predominantly weighted toward ambulatory function and routinely fails to capture subtle functional loss across cognitive, sensory, and upper-limb domains. To address this diagnostic gap, an international expert panel affiliated with the ParadigMS Foundation published a comprehensive practical framework in the Journal of Neurology detailing a step-by-step clinical methodology designed to identify and verify insidious disability progression across routine practice settings.
The initial stage of the clinical framework centers on identifying individuals who are at heightened risk of disability progression through proactive anamnesis and the systematic exclusion of confounding events. Clinicians must establish that the patient has a confirmed diagnosis of multiple sclerosis established under the McDonald criteria, maintains optimal disease-modifying treatment to control focal inflammatory activity, and has remained free from clinical relapses for at least three months prior and one month following testing. This timing constraint prevents relapse-associated worsening or new focal inflammatory lesions from being misattributed to silent progression. Because patients often adapt to or overlook minor functional losses, clinicians are urged to conduct comprehensive inquiries regarding symptom evolution since prior evaluations, focusing on motor endurance, cognitive processing, quality of life, pain, emotional health, and bladder, bowel, or sexual dysfunction, alongside screening for non-multiple sclerosis comorbidities such as metabolic, cardiovascular, or psychiatric disorders.
Physical and motor assessments form the bedrock of the secondary evaluation phase, utilizing sensitive testing batteries that extend beyond conventional examination scores. The traditional disability scale frequently misses mild walking impairments and subclinical functional loss; researchers have documented that measurable sub-threshold neurological deficits can occur even in individuals with an Expanded Disability Status Scale score of zero. To overcome these limitations, the authors recommend longitudinal monitoring using the Timed 25-Foot Walk test, the 6-Minute Walk Test, and the Six-Spot Step Test to quantify distinct parameters including walking velocity, endurance, and coordination. Incorporating the 9-Hole Peg Test to measure upper-limb dexterity within composite measures like the EDSS-plus allows clinicians to identify meaningful worsening, defined as a confirmed 20 percent or greater decline across follow-up intervals.
Cognitive evaluations represent another vital component of the diagnostic pathway, as cognitive deterioration often arises early in the disease course and serves as an independent prognostic indicator of long-term disability accumulation. The Symbol Digit Modalities Test is highlighted as a rapid, practical assessment capable of predicting disease progression up to ten years in advance. Clinical evidence demonstrates that an 8-point score reduction over a six-month interval at an 80 percent confidence interval indicates statistically relevant cognitive decline, while a 7-point change detects deterioration with 90 percent confidence after adjusting for practice effects and test-retest variability. To avoid testing habituation, clinicians must account for learning effects when administering tests every three to six months by randomizing symbol-number keys and testing sequences. Comprehensive assessment batteries such as the Brief International Cognitive Assessment for Multiple Sclerosis, which incorporates memory and visuospatial evaluations, provide deeper baseline metrics against which age- and demographic-adjusted performance can be tracked annually.
Standardized patient-reported outcome measures capture the broad spectrum of daily challenges that escape formal neurological examinations, particularly fatigue, mood disorders, and quality-of-life fluctuations. The authors advise using validated instruments such as the Modified Fatigue Impact Scale, where a 4-point increase signifies clinically meaningful deterioration, or the PROMIS Fatigue 8a questionnaire, which carries an established minimal important difference threshold of 3.4 to 4 points. In addition, psychiatric comorbidities require careful longitudinal screening, as up to half of all patients experience depression, and registry data link early depressive symptoms to accelerated disability accrual. Administering the Hospital Anxiety and Depression Scale helps monitor emotional status, where score changes of 1.5 to 1.7 points per subscale or 3 to 4 points overall indicate meaningful clinical shifts, though clinicians must carefully differentiate non-specific emotional stress from genuine neurodegenerative progression.
Advanced magnetic resonance imaging techniques provide structural verification of underlying tissue damage that correlates directly with clinical deterioration. Research shows that accelerated whole-brain atrophy, regional grey matter loss, and spinal cord volume reduction occur from early disease stages and directly predict future progression events. Furthermore, the presence of focal lesions yields substantial prognostic value: patients presenting with seven or more cortical lesions at baseline exhibit a shortened time to secondary progressive conversion, with 50 percent transitioning within 6.5 years. Spinal cord involvement serves as another critical indicator, where even a single baseline spinal lesion elevates long-term risk for progression independent of relapse activity. The detection of chronic active lesions, specifically paramagnetic rim lesions identified via susceptibility-sensitive MRI sequences, denotes persistent compartmentalized inflammation; individuals harboring four or more paramagnetic rim lesions display accelerated brain volume loss, earlier motor and cognitive impairment, and a 3.2-fold increase in progressive disease prevalence.
Fluid biomarkers and neurophysiological testing modalities deliver complementary biological evidence regarding axonal destruction and functional pathway compromise. In parallel, optical coherence tomography measures retinal neurodegeneration, with studies revealing that silent progression is linked to an accelerated loss of 1.8 micrometers in macular ganglion cell and inner plexiform layer thickness alongside 1.9 micrometers in peripapillary retinal nerve fiber layer thickness, while multimodal evoked potentials track subclinical transmission slowing across central motor and sensory pathways.
The concluding phase of the framework guides clinicians in synthesizing physical, biological, and imaging findings to confirm ongoing progression and adapt therapeutic management accordingly. When patients exhibit confirmed clinical decline across validated testing batteries or display unambiguous subclinical deterioration across multiple imaging and fluid biomarker indicators, clinicians are advised to consider adjusting disease-modifying therapies, particularly with disability-targeting agents such as Bruton’s tyrosine kinase inhibitors entering clinical development, while optimizing symptomatic therapies. The authors emphasize that clinicians must remain vigilant regarding confounding factors, noting that overlapping symptoms of biological aging, metabolic disorders, vascular disease, and adverse lifestyle habits can mimic or exacerbate neurodegenerative decline. Addressing modifiable risks through exercise, sleep optimization, smoking cessation, and comorbidity management remains critical to sustaining overall patient functioning.
Despite its clinical utility, the practical guidance acknowledges several operational limitations inherent to current real-world healthcare settings. The authors note that while their proposed cut-off thresholds are firmly grounded in peer-reviewed clinical studies and expert consensus, several specific numerical boundaries have not yet achieved formal prospective validation across generalized multiple sclerosis cohorts. Additionally, the recommended evaluation items are not hierarchically weighted, leaving clinicians to interpret cumulative findings without an algorithmic scoring system. Nevertheless, implementing systematic, multimodal evaluations establishes an objective baseline that enables neurologists to detect smouldering pathological activity far earlier than traditional examinations allow. Future advancements in electronic health record machine learning models and passive digital sensor tracking promise to refine these multi-domain assessments, ultimately supporting timely clinical interventions that protect neurological reserve.
Subject of Research: Clinical evaluation strategies for detecting progression independent of relapse activity in multiple sclerosis
Article Title: Uncovering disability progression in people with multiple sclerosis: a practical guide
Article References: Van Wijmeersch, B., Oreja-Guevara, C., Magyari, M., Airas, L., Chan, A., Deisenhammer, F., Grigoriadis, N., Hartung, H.-P., Pugliatti, M., Vermersch, P., Ziemssen, T., Drulovic, J., Alkhawajah, M. M., Zakaria, M., Popescu, V., & Pozzilli, C. (2026). Uncovering disability progression in people with multiple sclerosis: a practical guide. Journal of Neurology, 273(11), Article 699. https://doi.org/10.1007/s00415-026-14212-2
Image Credits: AI Generated
DOI: 10.1007/s00415-026-14212-2
Keywords: multiple sclerosis, progression independent of relapse activity, PIRA, Expanded Disability Status Scale, smouldering multiple sclerosis, neurology, neurodegeneration, biomarkers, serum neurofilament light chain, glial fibrillary acidic protein, magnetic resonance imaging, paramagnetic rim lesions, optical coherence tomography, evoked potentials, Timed 25-Foot Walk, Symbol Digit Modalities Test, patient-reported outcomes
News Source: Ophelia Keating. (November 15, 2026). Clinical Review Outlines Multimodal Strategy to Detect Silent Multiple Sclerosis Progression. Scienmag.



